In the present study, we classified the BLCA patients into two clusters and constructed the hypoxia score based on hypoxia‐related genes for predicting ICI treatment responsiveness, and hub gene TLR8 can be a suitable target for clinical immunotherapy in BLCA. Here, TLR8 is linked to bladder transitional cell carcinoma.